v3.26.1
Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Series A
Preferred Stock
Series D
Preferred Stock
Series E
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Accumulated Other Comprehensive Income
Due from Shareholders
Total Onconetix Equity (Deficit)
Total
Balance at Dec. 31, 2024     $ 127,825,744 $ (625,791) $ (115,683,621) $ (2,723,397) $ (250,308) $ 8,542,627  
Balance (in Shares) at Dec. 31, 2024       2,768              
Balance (in Shares) at Dec. 31, 2024           (3)          
Issuance of common stock in connection with the ELOC     4,776,309 250,308 5,026,617  
Issuance of common stock in connection with the ELOC (in Shares)       5,883              
Stock-based compensation expense     29,256 29,256  
Redemption of Series C Preferred Stock     (1,170,091) (1,170,091)  
Foreign currency translation adjustment     141,048 141,048  
Changes in pension benefit obligation     (30,779) (30,779)  
Net loss     (8,545,885) (8,545,885)  
Balance at Mar. 31, 2025     132,631,309 $ (625,791) (125,399,597) (2,613,128) 3,992,793  
Balance (in Shares) at Mar. 31, 2025     8,651              
Balance (in Shares) at Mar. 31, 2025           (3)          
Balance at Dec. 31, 2024     127,825,744 $ (625,791) (115,683,621) (2,723,397) (250,308) 8,542,627  
Balance (in Shares) at Dec. 31, 2024       2,768              
Balance (in Shares) at Dec. 31, 2024           (3)          
Net loss                     $ (10,918,327)
Balance at Jun. 30, 2025     135,021,441 $ (625,791) (128,100,543) (385,346)   $ 5,909,761
Balance (in Shares) at Jun. 30, 2025     20,181             3
Balance at Dec. 31, 2024     127,825,744 $ (625,791) (115,683,621) (2,723,397) (250,308) 8,542,627  
Balance (in Shares) at Dec. 31, 2024       2,768              
Balance (in Shares) at Dec. 31, 2024           (3)          
Balance at Dec. 31, 2025   147,836,004 $ (625,791) (131,214,558) (231,028)     $ 15,764,627
Balance (in Shares) at Dec. 31, 2025   16,325 7,813 31,201              
Balance (in Shares) at Dec. 31, 2025           (3)         3
Balance at Mar. 31, 2025     132,631,309 $ (625,791) (125,399,597) (2,613,128) $ 3,992,793  
Balance (in Shares) at Mar. 31, 2025     8,651              
Balance (in Shares) at Mar. 31, 2025           (3)          
Issuance of common stock in connection with the ELOC     1,365,038   $ 1,365,038
Issuance of common stock in connection with the ELOC (in Shares)       6,702              
Stock-based compensation expense     30,982   30,982
Cash in lieu of shares     (926)   (926)
Cash in lieu of shares (in Shares)       (2)              
Redemption of Series C Preferred Stock     (328,504)   (328,504)
Settlement of subscription agreement liability       995,038   995,038
Settlement of subscription agreement liability (in Shares)       4,830              
Foreign currency translation adjustment     1,882,464   1,882,464
Changes in pension benefit obligation     (345,318)   (345,318)
Net loss     (2,372,442)   (2,372,442)
Balance at Jun. 30, 2025     135,021,441 (625,791) (128,100,543) (385,346)   $ 5,909,761
Balance (in Shares) at Jun. 30, 2025     20,181             3
Balance at Dec. 31, 2025   147,836,004 $ (625,791) (131,214,558) (231,028)     $ 15,764,627
Balance (in Shares) at Dec. 31, 2025   16,325 7,813 31,201              
Balance (in Shares) at Dec. 31, 2025           (3)         3
Stock-based compensation expense   22,305     $ 22,305
Conversion of Series E Preferred Stock to Common Stock      
Conversion of Series E Preferred Stock to Common Stock (in Shares)     (232) 7,656              
Conversion of Series D Preferred Stock to Common Stock   $ 2 (2)    
Conversion of Series D Preferred Stock to Common Stock (in Shares)   (6,373)   222,265              
Issuance of Common Stock for Warrant Exercise   384,842     384,842
Issuance of Common Stock for Warrant Exercise (in Shares)       14,409              
Cancellation of restricted common stock      
Cancellation of restricted common stock (in Shares)       (13)              
Cash in lieu of shares   (250)     (250)
Cash in lieu of shares (in Shares)       (1)              
Foreign currency translation adjustment   (210,172)     (210,172)
Net loss   (4,214,875)     (4,214,875)
Balance at Mar. 31, 2026   $ 2 148,242,899 $ (625,791) (135,429,433) (441,200)     11,746,477
Balance (in Shares) at Mar. 31, 2026   9,952 7,581 275,517              
Balance (in Shares) at Mar. 31, 2026           (3)          
Balance at Dec. 31, 2025   147,836,004 $ (625,791) (131,214,558) (231,028)     $ 15,764,627
Balance (in Shares) at Dec. 31, 2025   16,325 7,813 31,201              
Balance (in Shares) at Dec. 31, 2025           (3)         3
Conversion of Series E Preferred Stock to Common Stock (in Shares)     668,021                
Net loss                     $ (7,082,178)
Balance at Jun. 30, 2026   $ 38 152,959,715 $ (625,791) (138,296,736) (568,717)     $ 13,468,509
Balance (in Shares) at Jun. 30, 2026   8,156 3,793,676              
Balance (in Shares) at Jun. 30, 2026           (3)         3
Balance at Mar. 31, 2026   $ 2 148,242,899 $ (625,791) (135,429,433) (441,200)     $ 11,746,477
Balance (in Shares) at Mar. 31, 2026   9,952 7,581 275,517              
Balance (in Shares) at Mar. 31, 2026           (3)          
Issuance of common stock in connection with the ELOC   $ 27 4,265,248     4,265,275
Issuance of common stock in connection with the ELOC (in Shares)       2,704,126              
Stock-based compensation expense   7,359     7,359
Conversion of Series E Preferred Stock to Common Stock   $ 7 331,417     331,424
Conversion of Series E Preferred Stock to Common Stock (in Shares)     (7,581) 660,365              
Conversion of Series D Preferred Stock to Common Stock   $ 2 112,890     112,892
Conversion of Series D Preferred Stock to Common Stock (in Shares)   (1,796)   153,712              
Cancellation of restricted common stock      
Cancellation of restricted common stock (in Shares)       (26)              
Cash in lieu of shares   (98)     (98)
Cash in lieu of shares (in Shares)       (18)              
Foreign currency translation adjustment   (127,517)     (127,517)
Net loss   (2,867,303)     (2,867,303)
Balance at Jun. 30, 2026   $ 38 $ 152,959,715 $ (625,791) $ (138,296,736) $ (568,717)     $ 13,468,509
Balance (in Shares) at Jun. 30, 2026   8,156 3,793,676              
Balance (in Shares) at Jun. 30, 2026           (3)         3